These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37018470)

  • 1. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.
    Muller WJ; Madhi SA; Seoane Nuñez B; Baca Cots M; Bosheva M; Dagan R; Hammitt LL; Llapur CJ; Novoa JM; Saez Llorens X; Grenham A; Kelly EJ; Mankad VS; Shroff M; Takas T; Leach A; Villafana T;
    N Engl J Med; 2023 Apr; 388(16):1533-1534. PubMed ID: 37018470
    [No Abstract]   [Full Text] [Related]  

  • 2. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
    Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T;
    N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palivizumab for the prevention of respiratory syncytial virus infection.
    Rogovik AL; Carleton B; Solimano A; Goldman RD
    Can Fam Physician; 2010 Aug; 56(8):769-72. PubMed ID: 20705882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
    Bergeron HC; Tripp RA
    Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
    Domachowske J; Madhi SA; Simões EAF; Atanasova V; Cabañas F; Furuno K; Garcia-Garcia ML; Grantina I; Nguyen KA; Brooks D; Chang Y; Leach A; Takas T; Yuan Y; Griffin MP; Mankad VS; Villafana T;
    N Engl J Med; 2022 Mar; 386(9):892-894. PubMed ID: 35235733
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
    Yeo KT; Yung CF; Khoo PC; Saffari SE; Sng JSP; How MS; Quek BH
    J Infect Dis; 2021 Jul; 224(2):279-287. PubMed ID: 33274362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.
    Chi H; Hsu CH; Chang JH; Chiu NC; Hung HY; Kao HA; Weng LC; Huang FY; Chiu YY; Chang LY; Huang LM
    PLoS One; 2014; 9(6):e100981. PubMed ID: 24971565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
    Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
    N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals.
    Galvis C; Colmenares A; Cabrales L; Ibatá L; Marulanda J; Ovalle O; Puello D; Rojas C; Africano M; Ballesteros A; Posso H
    Pediatr Pulmonol; 2022 Oct; 57(10):2420-2427. PubMed ID: 35791790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
    Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
    N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
    Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K
    Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
    Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
    Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
    Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
    J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
    Forbes ML; Kumar VR; Yogev R; Wu X; Robbie GJ; Ambrose CS
    Hum Vaccin Immunother; 2014; 10(10):2789-94. PubMed ID: 25483663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection.
    Lanari M; Vandini S; Arcuri S; Galletti S; Faldella G
    Clin Dev Immunol; 2013; 2013():359683. PubMed ID: 23840240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper.
    Esposito S; Abu-Raya B; Bonanni P; Cahn-Sellem F; Flanagan KL; Martinon Torres F; Mejias A; Nadel S; Safadi MAP; Simon A
    Front Immunol; 2021; 12():708939. PubMed ID: 34456918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.
    Paes B; Mitchell I; Li A; Lanctôt KL
    Eur J Pediatr; 2012 May; 171(5):833-41. PubMed ID: 22203430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.